Page last updated: 2024-09-05

deferasirox and Diabetes Mellitus

deferasirox has been researched along with Diabetes Mellitus in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Amendola, G; Casale, M; Cinque, P; Citarella, S; De Michele, E; Della Rocca, F; Filosa, A; Nobili, B; Palmieri, F; Perrotta, S; Pugliese, U; Ragozzino, A; Tartaglione, I	1
Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V	1
Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F	1
Edwards, JE; French, SW; Fu, Y; Gebermariam, T; Husseiny, MI; Ibrahim, AS; Lin, L; Schwartz, J; Skory, CD; Spellberg, BJ	1

Trials

1 trial(s) available for deferasirox and Diabetes Mellitus

Article	Year
Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major. American journal of hematology, 2014, Volume: 89, Issue:12 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Bone and Bones; Bone Density; Calcium; Chelation Therapy; Child; Child, Preschool; Deferasirox; Diabetes Mellitus; Diphosphonates; Female; Humans; Hypogonadism; Hypoparathyroidism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Puberty, Delayed; Retrospective Studies; Triazoles; Vitamin D	2014

Article

Year

Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.

American journal of hematology, 2014, Volume: 89, Issue:12

Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Bone and Bones; Bone Density; Calcium; Chelation Therapy; Child; Child, Preschool; Deferasirox; Diabetes Mellitus; Diphosphonates; Female; Humans; Hypogonadism; Hypoparathyroidism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Puberty, Delayed; Retrospective Studies; Triazoles; Vitamin D

2014

Other Studies

3 other study(ies) available for deferasirox and Diabetes Mellitus

Article	Year
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. Annals of hematology, 2016, Volume: 95, Issue:5 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypogonadism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Prevalence; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles	2016
Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox. Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:1 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Creatinine; Cross-Sectional Studies; Deferasirox; Deferiprone; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Proteinuria; Pyridones; Transfusion Reaction; Triazoles; Young Adult	2017
The iron chelator deferasirox protects mice from mucormycosis through iron starvation. The Journal of clinical investigation, 2007, Volume: 117, Issue:9 Topics: Amphotericin B; Animals; Benzoates; Deferasirox; Diabetes Mellitus; Drug Therapy, Combination; Iron; Iron Chelating Agents; Liposomes; Male; Mice; Mice, Inbred BALB C; Mucorales; Mucormycosis; Survival Rate; Th1 Cells; Th2 Cells; Triazoles	2007